| Objective: To observe the clinical efficacy of Pei’s liver cancer recipe in the treatment of primary liver cancer after TACE(dampness-heat accumulation syndrome),and to evaluate the efficacy and safety of Pei’s liver cancer recipe in patients with primary liver cancer after TACE.Methods: 60 cases of primary liver cancer after TACE(damp-heat accumulation syndrome)were randomly divided into two groups: treatment group(n=30)and control group(n=30).The treatment group was treated with Pei’s liver cancer prescription combined with western medicine routine therapy,while the control group was given only symptomatic supportive treatment,taking medicine for 4 weeks as a course of treatment.The quality of life(KPS scale),TCM symptom score,liver function,AFP,imaging tumor size,blood routine and renal function were measured,and the safety of Pei’s liver cancer prescription was evaluated.Results:(1)Comparison of therapeutic effects of solid tumors:the total effective rate of treatment group was 56.67,and the disease control rate was 96.67 in the treatment group,while in the control group the total effective rate was 50.0086.67.There was no apparent difference between the two groups in solid tumors by rank sum test of two independent samples(P>0.05).(2)Serum AFP level:the mean value before treatment was 511.91±117.54 in the treatment group,305.35±78.11 after the treatment,and 520.77±141.14 before treatment in the control group,314.03±105.99 after the treatment.The serum AFP of the two groups decreased after treatment,but it was significantly lower in the treatment group than that in the control group(P<0 01).(3)Liver function(ALT,AST)level:the mean value of ALT was 109.58±57.53 before treatment,39.27±9.63 after treatment in treatment group,116.56±53.98 in control group,49.83±12.37 in control group.ALT decreased more obviously after treatment in treatment group,which has statistically meaningful(P<0.01).The mean AST before treatment was 119.48±84.32 in the treatment group,41.71±14.28 in thecontrol group,and 123.77±83.57 in the control group.The AST of the treatment group was well below one of the control group(P<0.05).(4)The clinical symptoms of TCM:In the treatment group,17 cases(56.6%)were effective,10(33.3%)cases were effective,the total effective rate was 90%,and the control group was 10 cases(33.3%),13 cases(43.3%).Comparison between the two groups,the treatment group was significantly better than the control group(P <0.05).(5)Quality of life(KPS score): the average value before treatment was 78.67±13.32 in the treatment group,87.33±11.72 after the treatment,and 79.67±14.05 before treatment in the control group and 80.66±13.37 in the control group.The KSP scores of the two groups increased after treatment,but the increase of the treatment group was more obvious,the difference was statistically significant(P<0 05).(6)Safety index:1Blood routine:the mean value of WBC treatment group was5.59±2.04 before treatment,5.25±1.40 after treatment,5.90±2.09 before treatment in control group and 5.50±0.83 after treatment.The mean value of hemoglobin treatment group was 121.46±22.22 before treatment,125.73±18.70 after treatment,and120.8±20.40 before treatment and 112.5±18.54 after treatment in control group.The mean value of platelet therapy group was 206.16±50.66 before treatment and206.7±48.27 after treatment.210.16±57.65 before treatment and 200.06±58.31 after treatment in the group A,There was no significant difference in average value(P>0.05).2 Renal function:the level of urea nitrogen and creatinine did not change significantly before and after treatment in both groups(P>0.05).Conclusion: In order to reduce the AFP level and the liver function of the patients with liver cancer,we can improve the clinical symptom and score of the traditional Chinese medicine,prevent the decrease of the KSP score,improve the quality of life and the safety and non-toxic side effect. |
PDF Full Text Request